Literature DB >> 10640442

Characterization of proximal transcription regulatory elements in the rat phospholamban promoter.

C F McTiernan1, B H Lemster, C S Frye, D C Johns, A M Feldman.   

Abstract

Phospholamban is a major regulator of cardiac diastole, with alterations in expression associated with modified cardiac relaxation. To study transcriptional regulation of phospholamban expression, we made reporter constructs that expressed luciferase under control of putative promoter sequences from the rat phospholamban gene. When transfected into neonatal rat cardiomyocytes, constructs containing at least 159 nucleotides preceding the transcription start site were equally active, while truncation to -66/+64 removed all promoter activity. Constructs were more active in cardiomyocytes than in HeLa cells (which do not express phospholamban), but did not show absolute cell-type specificity of expression. Addition of sequences upstream to -4032, all of the intron (7.4 kb), or 3'UTR sequences (0. 8 kb) did not enhance cell-specific expression. To focus on the basal promoter region (-159/-66), a series of deletion constructs were made that identified a novel 35 bp region (-159/-125; Phospholamban Promoter Element 1, PPE1) required for promoter activity in cardiomyocytes. Site-specific mutations identified nucleotides -150/-133 as containing most of the promoter-enhancing activity. While the rat PPE1 is highly conserved (>70%) in four other mammalian phospholamban genes, it does not contain previously characterized regulatory elements. In cardiomyocytes the PPE1 sequence markedly enhanced activity of the SV40 early promoter. A conserved CCAAT element (-83/-79) was also required for promoter activity in both cardiomyocytes and HeLa cells. Exonuclease III footprinting identified protein/DNA interactions in both the extended CCAAT box and PPE1 domains. Gel shift studies identified the CCAAT elements as binding CBF/NF-Y. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10640442     DOI: 10.1006/jmcc.1999.1042

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  4 in total

1.  Repression of cardiac phospholamban gene expression is mediated by thyroid hormone receptor-{alpha}1 and involves targeted covalent histone modifications.

Authors:  Madesh Belakavadi; Jason Saunders; Noah Weisleder; Preethi S Raghava; Joseph D Fondell
Journal:  Endocrinology       Date:  2010-04-14       Impact factor: 4.736

2.  HuR regulates phospholamban expression in isoproterenol-induced cardiac remodelling.

Authors:  Han Hu; Mingyang Jiang; Yangpo Cao; Zhuojun Zhang; Bin Jiang; Feng Tian; Juan Feng; Yali Dou; Myriam Gorospe; Ming Zheng; Lemin Zheng; Zhongzhou Yang; Wengong Wang
Journal:  Cardiovasc Res       Date:  2020-04-01       Impact factor: 10.787

3.  A human phospholamban promoter polymorphism in dilated cardiomyopathy alters transcriptional regulation by glucocorticoids.

Authors:  Kobra Haghighi; Guoli Chen; Yoji Sato; Guo-Chang Fan; Suiwen He; Fotis Kolokathis; Luke Pater; Ioannis Paraskevaidis; W Keith Jones; Gerald W Dorn; Dimitrios Th Kremastinos; Evangelia G Kranias
Journal:  Hum Mutat       Date:  2008-05       Impact factor: 4.878

4.  Cardiac Gene Expression Knockdown Using Small Inhibitory RNA-Loaded Microbubbles and Ultrasound.

Authors:  Jonathan A Kopechek; Andrew R Carson; Charles F McTiernan; Xucai Chen; Edwin C Klein; Flordeliza S Villanueva
Journal:  PLoS One       Date:  2016-07-29       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.